Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opioid Use Disorder App Marks A Path For 510(k) 'Breakthrough' Devices

Executive Summary

Pear Therapeutics announced US Expedited Access Pathway designation earlier this month for its 510(k)-route reSET-O Prescription Digital Therapeutic for OUD, perhaps providing some insight into the types of products seeking a "substantial equivalence" claim that might, nonetheless, be considered breakthroughs.


Related Content

Pear Picks Up Prescription Opioid App Clearance
Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology
Medtech Tools To Help Address Opioid Crisis Face Reimbursement Challenges
US Approvals Analysis: Hits Just Keep On Coming. Can It Last?
Five Takeaways From Commissioner Gottlieb's Talk At The National Press Club
'Breakthrough' Blueprint: US FDA Draft Guideline Outlines Revised Expedited Development Program
'Excellence' In Health-Software Design: US FDA Taps Nine Firms To Figure Out What That Means
First Anti-Addiction App Approved In The US
US FDA Ready To Accept 510(k) Devices To Expedited Access/Breakthrough Pathway





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts